Arbutus Biopharma Corp ABUS

Healthcare Biotechnology

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.

NDAQ:ABUS - Post by User

Arbutus Biopharma Corp

Bullboard Posts

Post by grover11on Jul 31, 2014 8:12pm

250 Views

Post# 22800647

Anyone catch this???

I filled the petition out yesterday when it came out.. 10,000 strong already. Anyways, curious if anyone is aware if this latest development???!

10,000 and rising

Ahmed Tejan-Sie MD

31 Jul 2014 — I didn't think I'd be providing another update so soon,thanks again for your tremendous support. Today CNN has reported that one of the American aid workers infected with Ebola in Liberia has been treated with TKM-Ebola and is being medically evacuated to to the USA.
Continue to support this petition by distributing it to as many of your friends and colleagues as possible. Let's make this petition successful so TKM- Ebola can be fully developed and made available to the rest of the world. Once again let's save lives together.

Bullboard Posts

Investors eye Australian gold mining projects amid promising developments